Select Page

Titan Biotech (Small Cap - Potential Multibagger) Share Target 2025, 2026 To 2035

Titan Biotech Limited

Company Logo Price: ₹752.50 (-0.78%)
52 Week Low: ₹440.00
52 Week High: ₹1,017.85
Market Capital: 450.12 Crore (Smallcap)
->
Show Table of Contents

Titan Biotech, a Small Cap company has delivered 1797.9% returns in 5-year showing 5.9% quarterly revenue growth with 51.5% profit margin, making it a potential Multibagger.

To predict the Titan Biotech's future market prices, we harnessed 2 dynamic approaches:

Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices

Approach 1: Technical Analysis Paired With Price Action

Titan Biotech Share Price Target For 2025

The line chart displays the monthly closing prices of Titan Biotech with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.

For detailed target and stop loss values for Titan Biotech shares in 2025, see the table below.

Titan Biotech Share Price Target Table For 2025

Level Value Analysis
2025 Target 3 860.0 (+14.28%) Price Action: 11 Nov 2024 Low
2025 Target 2 846.3 (+12.46%) Price Action: 09 Dec 2024 Low
2025 Target 1 837.9 (+11.34%) Price Action: 11 Dec 2024 High
Current Price 752.50 Titan Biotech's share price as of 23 Jan 2025
Stop Loss 1 713.95 (-5.13%) Price Action: 26 Sep 2024 High
Stop Loss 2 705.1 (-6.3%) Price Action: Dec 2024 Low
Stop Loss 3 693.0 (-7.91%) Price Action: 19 Sep 2024 Low

Short-Term Technical Outlook

Current Technical Position: Titan Biotech is showing mixed momentum signals near key moving averages.

Key Technical Level: The 25-day moving average at ₹749.58 serves as the nearest technical reference point.

Historical Returns: 3-month: -18.2% | 6-month: +30.38% | 1-year: +51.83%

Titan Biotech Share Price Target For 2026

The line chart displays the monthly closing prices of Titan Biotech with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.

For detailed target and stop loss values for Titan Biotech shares in 2026, see the table below.

Titan Biotech Share Price Target Table For 2026

Level Value Analysis
2026 Target 3 1326.41 (+76.26%) Price Action: Chart
2026 Target 2 1301.68 (+72.98%) Price Action: Chart
2026 Target 1 1288.79 (+71.26%) Fibonacci Extension Level 64.90%
Current Price 752.50 Titan Biotech's share price as of 23 Jan 2025
Stop Loss 1 630.0 (-16.28%) Price Action: 01 Jul 2024 High
Stop Loss 2 621.0 (-17.48%) Price Action: 28 May 2024 High
Stop Loss 3 613.5 (-18.48%) Price Action: 09 Aug 2024 High

Long-Term Technical Outlook

52-Week Range Analysis: Titan Biotech is currently trading at 54.1% of its 52-week range (₹440 - ₹1017.85).

Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.

Long-Term Performance: 1-year: +51.83% | 3-year: +138.1% | 5-year: +1,797.86%

Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!

Join our WhatsApp group

Join our Telegram group

Your phone number will be HIDDEN to other users.

Approach 2: Machine Learning By Studying Historical Prices

Titan Biotech Share Price Target Chart and Table From 2025, 2026, 2027 to 2035

Year Target 1 Target 1 YoY Chg % Target 2
Current Price ₹752.50
2025 ₹1,132.93 +50.55% ₹1,149.92
2026 ₹1,594.76 +40.76% ₹1,618.68
2027 ₹1,935.12 +21.34% ₹1,964.15
2028 ₹2,651.90 +37.04% ₹2,691.68
2029 ₹3,951.14 +48.99% ₹4,010.41
2030 ₹4,976.44 +25.94% ₹5,051.09
2031 ₹6,665.74 +33.94% ₹6,765.73
2032 ₹8,789.09 +31.85% ₹8,920.93
2033 ₹12,396.08 +41.03% ₹12,582.02
2034 ₹15,940.90 +28.59% ₹16,180.01
2035 ₹20,964.30 +31.51% ₹21,278.76

Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.

Titan Biotech Financial Performance

Metric Value Description
Market Capital 450.12 Crore Market valuation of Titan Biotech's shares.
Revenue (TTM) 143.99 Crore Total revenue generated by Titan Biotech over the past twelve months.
Net Income (TTM) +24.84 Crore Net Profit or Loss after all the expenses over the past twelve months.
Operating Margin +20.04% Income from operations as a percentage of revenue, before taxes and interest.
Profit Margin +51.47% Net income as a percentage of revenue, after all expenses.
Revenue Growth
(Quarterly)
+5.87% Change in revenue compared to the previous quarter.
Debt-to-Equity
(D/E) Ratio
0.07 Company's total debt divided by total shareholder equity.
Total Debt 8.56 Crore Sum of Titan Biotech's current & long-term financial obligations.

Is Titan Biotech A Good Buy For Long Term?

Titan Biotech's strong financial performance, with a 51.47% profit margin and consistent revenue growth of 5.87% in the last quarter, indicates its potential as a long-term investment. The company's impressive past returns, including a 131.78% return over the last year and a 264.59% return over the last 3 years, further support its growth trajectory. However, it's important to note the company's debt of 8.56 Crore, which may require further analysis to assess its impact on future profitability. Overall, Titan Biotech appears to be a promising investment opportunity for long-term investors seeking growth potential.

Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.

All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.